

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 May 2023 (25.05.2023)



(10) International Publication Number
WO 2023/092090 A1

(51) International Patent Classification:
A61K 39/09 (2006.01)

Kevin P., 339 Country Way, Needham, Massachusetts 02492 (US).

(21) International Application Number:
PCT/US2022/080168

(74) Agent: **ELRIFI, Ivor R.** et al.; 1299 Pennsylvania Ave. NW, Suite 700, Washington, District of Columbia 20004 (US).

(22) International Filing Date:
18 November 2022 (18.11.2022)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/280,908 18 November 2021 (18.11.2021) US

(71) Applicant: **MATRIVAX, INC.** [US/US]; c/o Matrivax Research & Development Corp., 22 Boston Wharf Rd, Boston, Massachusetts 02210 (US).

(72) Inventor; and

(71) Applicant: **MORAN, Enda** [IE/US]; c/o Matrivax Research & Development Corp., 22 Boston Wharf Rd, Boston, Massachusetts 02210 (US).

(72) Inventors: **CARTEE, Robert Thompson**; 30 Smiths Lane, Kingston, Massachusetts 02364 (US). **KILLEEN,**

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

(54) Title: IMMUNOGENIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF




FIG. 1A




FIG. 1B

(57) Abstract: The disclosure relates to immunogenic fusion protein compositions and methods of use thereof for preventing or treating pneumococcal infection. The disclosure relates to methods of producing and purifying immunogenic fusion proteins. This disclosure further relates to compositions and formulations comprising immunogenic fusion proteins.

[Continued on next page]

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))